Free Trial
→ Elon Musk… A Total Fraud? (From Brownstone Research) (Ad)tc pixel
NASDAQ:IRWD

Ironwood Pharmaceuticals Q3 2026 Earnings Date & Estimates

Ironwood Pharmaceuticals logo
$3.50 -0.12 (-3.31%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$3.50 0.00 (-0.14%)
As of 10/30/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ironwood Pharmaceuticals is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Ironwood Pharmaceuticals in Q3 2026

Ironwood Pharmaceuticals is expected to post earnings of $0.3233 per share on revenue of $119.99 million. In the same quarter a year earlier Ironwood Pharmaceuticals reported $0.24 per share on revenue of $122.06 million. Ironwood Pharmaceuticals last reported on August 6, 2026, posting $0.31 per share and missing the $0.32 consensus estimate. Ironwood Pharmaceuticals has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.3233
Expected Revenue
$119.99 million
Prior-Year EPS
$0.24
Prior-Year Revenue
$122.06 million
Expected EPS Growth
+34.7%
Expected Revenue Growth
-1.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.31 (Missed by -$0.01)
Last Quarter Revenue
$113.04 million
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Ironwood Pharmaceuticals Q3 2026 Earnings FAQ

Ironwood Pharmaceuticals (NASDAQ:IRWD) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Ironwood Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Ironwood Pharmaceuticals to post earnings of $0.3233 per share for Q3 2026.

The consensus revenue estimate for Ironwood Pharmaceuticals is $119.99 million for Q3 2026.

Ironwood Pharmaceuticals Earnings Headlines

Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call
October 28 at 8:53 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ironwood-pharmaceuticals-host-third-quarter-200500477.html
Ironwood Pharmaceuticals CEO Tom McCourt to Retire; Chief Commercial Officer Tammi Gaskins Named Successor
October 16, 2026  |  marketscreener.comM
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
 |  Porter & Company (Ad)
Ironwood Pharmaceuticals Promotes COO Tammi Gaskins To Succeed Tom McCourt As CEO
October 16, 2026  |  rttnews.comhttps://www.rttnews.com/3699765/ironwood-pharmaceuticals-promotes-coo-tammi-gaskins-to-succeed-tom-mccourt-as-ceo.aspx
Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer
October 16, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261016751818/en/Ironwood-Pharmaceuticals-Appoints-Tammi-Gaskins-as-Chief-Executive-Officer/
Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy
October 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4952469-ironwood-pharmaceuticals-the-stock-is-a-call-on-the-second-apraglutide-trial-buy?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
See More Ironwood Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ironwood Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ironwood Pharmaceuticals and other key companies, straight to your email.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ:IRWD) is a gastrointestinal-focused biopharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines intended to treat disorders affecting the gastrointestinal tract, with an emphasis on conditions involving gut motility and visceral sensitivity.

Ironwood’s principal commercial product is Linzess (linaclotide), marketed in the United States in collaboration with AbbVie. Linzess is approved for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The product is also marketed in certain international markets under the name Constella through regional partnerships.

Founded in 1998, Ironwood has expanded from a development-stage biotechnology company into a commercial biopharmaceutical business. In addition to supporting the continued development and commercialization of linaclotide, the company maintains a pipeline of investigational gastrointestinal therapies designed to address significant unmet medical needs.

Ironwood is led by Chief Executive Officer Tom McCourt. Its products and development activities serve patients in the United States and selected international markets through direct commercial operations and collaborations with other pharmaceutical companies.

View Ironwood Pharmaceuticals Profile
Earnings Tools